Tracers / [177Lu]Lu-LNC1010
[177Lu]Lu-LNC1010
Also written as [Lu-177]Lu-LNC1010; Lu-177-LNC1010
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- first-in-human
- Syntheses indexed
- 1
What it is
- Compound class
- SSTR2-targeting somatostatin analog peptide with Evans blue albumin-binding moiety (long-acting somatostatin analog)
- Target / mechanism
- SSTR2 agonist (somatostatin receptor subtype 2) PMID 40177560
- Clinical application
- Peptide receptor radionuclide therapy (PRRT) in patients with advanced/metastatic neuroendocrine tumors PMID 40177560
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | LNC1010 | 40177560 2025 Acta Pharm Sin B 370–740 MBq 177LuCl3 was mixed with LNC1010 (100–200 μg) and diluted with 0.2 mL of 0.5 mol/L NaOAc (pH = 5.5) and heated reaction at 95 °C for 30 min. |
Need this precursor?We can point you to suppliers for [177Lu]Lu-LNC1010, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 40177560: 'we presented the first-in-human dose escalation study of 177Lu-LNC1010 in patients with advanced/metastatic NETs'.